Who are Dianthus Therapeutics?
Launching officially following this funding round, Dianthus Therapeutics are known for designing monoclonal antibodies with heightened selectivity, in the aim of assisting people living with severe and rare autoimmune diseases. Patients are provided with less frequent, lower doses with the goal of more agency in their lives.
CEO Marino Garcia co-founded the team with a demonstrated history of leadership in life sciences. Garcia is known for management and marketing roles with Pfizer, Aspera Pharmaceuticals and Zealand Pharma, as well as four years as Vice President at Aptalis Pharma. Likewise, CEO, President and co-founder Jonathan Violin holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, among other healthcare qualifications.
IQVIA predicts that the $1.2 trillion 2018 value of the pharmaceutical industry will increase by 2023 to $1.5 trillion. Remote vacancies are posted at this time for offices in Waltham, MA and New York City, NY. As the group undoubtably expands, Talent Ticker looks forward to upcoming impressive growth whilst Dianthus Therapeutics develops their products and clientele base.
Things are looking rosy for the team, having raised £121.5m over three funding rounds in just three years. The initial $21.5m, raised via $6.5m in 2019 and £15m in 2021, was used to begin preliminary pharmaceutical drug development. With fast development and no sign of slowing down, Talent Ticker prescribes one treatment to Dianthus Therapeutics- hire!
Check out www.talentticker.ai to find out how we can help you generate more leads to make your recruiting more efficient and effective.
Talent Ticker’s AI analyses the world’s news and data to predict which companies are likely to hire in the near future. To learn more about some of our highlighted up-and-coming companies, click here or have a look at our last Story of the Week.